Medicines For Europe Urges Intervention In Inflation Crisis
Industry Conditions Have Exacerbated Impact Of Ukraine War And COVID-19
Medicines for Europe has called for alterations to regulations concerning the off-patent drug sector, which it says will allow the industry to respond more effectively to the region’s dramatic rise in inflation.
You may also be interested in...
In the second part of a three-part interview with Generics Bulletin, Medicines for Europe director general Adrian van den Hoven discusses the rise in prominence of biosimilars in Europe, reflects on off-patent industry efforts to deal with crises such as the COVID-19 pandemic and the war in Ukraine, and highlights achievements such as the SPC manufacturing waiver.
Rising inflation has exacerbated pressures in the off-patent drug sector, prompting Medicines for Europe and the US Association for Accessible Medicines to call for regulatory intervention to ensure the long-term sustainability of the space.
Medicines For Europe and Czech association CAFF demand EU and national reforms to help drug makers ensure supply and patient access, particularly in Central and Eastern Europe.